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Monoclonal antibodies bevacizumab and cetuximab both improve overall survival (OS), progression free survival
(PFS) and overall response rate (ORR) when combined with irinotecan-containing regimens. The optimal sequence
of these monoclonal antibodies in combination with chemotherapy is controversial. This study analysed the efficacy
of cetuximab plus Folfiri after progression with the same regimen plus bevacizumab in patients with metastatic
colorectal cancer (mCRC). Patients are eligible if progressive disease (PD) after Folfiri-bevacizumab; ECOG PS 0–1.
Primary endpoint is the disease control rate (DCR:ORR plus stable disease > 6 months); secondary endpoints: ORR,
PFS, duration of response, OS and toxicity. ORR and DCR were reported with their confidence interval at 95%.
Kaplan-Meier method was used for PFS and OS evaluation. Results: 54 patients were enrolled to receive Folfiri-
cetuximab after PD to Folfiri-bevacizumab treatment. Median age was 65 (43–80), M/F 31/23, ECOG PS 0/1 was
36/ 18, WT Kras 33(61%). The DCR was 64.8% (CI 95% 52.1-77.5). Among the group of patients with stable or
progressive disease at first line treatment, 13.3% of them obtained a response at second line. For second line
treatment median duration of response was 6 months and clinical benefit 7 months. The ORR was 22.2% (CI 95%
11.1-33.3). The median progression-free survival was 7 months (CI 95% 6–8). The median overall survival for second
line treatment was 14 months (CI 95% 11–17). No grade 4 toxicity was observed. Data suggest that this sequential
combination therapy is active and well tolerated. At disease progression to first line chemotherapy treatment the
maintenance of the same chemotherapy regimen and the change of the monoclonal antibody showed efficacy in
response and survival in patients with mCRC.
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Colorectal cancer is a major cause of morbidity and
mortality worldwide. Nowadays the median duration of
survival among patients with advanced colorectal cancer
has been increased through the introduction of new
drugs. Survival has reached about twenty-four months
(Van Cutsem et al. 2009).
These significant improvements are the result of new
combinations of standard drugs, such as fluorouracil,
irinotecan and oxaliplatin, in association with new thera-* Correspondence: robertagrande@virgilio.it
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in any medium, provided the original work is ppeutic agents, namely bevacizumab and cetuximab (De
Gramont et al. 2000; Douillard et al. 2000a; Giacchetti
et al. 2000; Goldberg et al. 2004a; Saltz et al. 2000a;
Cunningham et al. 1998; Rougier et al. 1998; Cunningham
et al. 2004a).
These monoclonal antibodies target molecular regions
involved in colorectal carcinogenesis. Bevacizumab, a
humanized monoclonal antibody directed against vascular
endothelial growth factor A (VEGF-A), improves response
rate (RR), progression-free survival (PFS) and overall
survival (OS) in combination with irinotecan when com-
pared with patients treated with chemotherapy treatment
alone (Hurwitz et al. 2004). Similar benefits in OS, PFSan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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adding bevacizumab to standard chemotherapy (Giantonio
et al. 2007).
Moreover, cetuximab, a human-murine chimeric mono-
clonal antibody that targets epidermal growth factor re-
ceptors (EGFR), has shown antitumor activity both alone
and in combination with irinotecan (Cunningham et al.
2004b; Saltz et al. 2001; Saltz et al. 2004; Lenz et al. 2006).
Until last year standard first-line chemotherapy included
fluorouracil with leucovorin and irinotecan or oxaliplatin,
alone or combined with bevacizumab (Douillard et al.
2000b; Saltz et al. 2000b; Goldberg et al. 2004b; Van
Cutsem & Geboes 2007).
Recently, CRYSTAL and OPUS studies have shown
the activity of cetuximab in first line chemotherapy
treatment in wild-type KRAS gene status. This gene is
predictor for resistance to epidermal growth factor re-
ceptor (EGFR) monoclonal antibody therapies (Van
Cutsem et al. 2009; Bokemeyer et al. 2009; McLellan
et al. 1993; Arber et al. 2000; De Roock et al. 2008; Di
Fiore et al. 2007b; Lièvre et al. 2008; Lièvre et al. 2006;
Cervantes et al. 2008).
However, the optimal sequence of these monoclonal
antibodies in combination with chemotherapy is contro-
versial and there are no studies suggesting what the
most effective sequence of these drugs is.
Therefore this study aims to evaluate the feasibility of
a sequential chemotherapy regimen. In particular it aims
to explore the efficacy of cetuximab in association with
irinotecan-based chemotherapy (Folfiri) after disease
progression with the same chemotherapy regimen
plus bevacizumab in patients with metastatic colorectal
cancer.Materials and methods
Patients were considered eligible if they had pathologic-
ally confirmed colorectal cancer, metastatic disease,
positive EGFR immunostaining. To be eligible, patients
must have received at least six months of first line
chemotherapy with Folfiri plus bevacizumab. Eligibility
criteria also included: age ≥18 years, Eastern Cooperative
Oncology Group (ECOG) performance status of ≤1;
normal hematopoietic function (haemoglobin, at least 9
g per decilitre [5.6 mmol per liter]; neutrophil count, at
least 1500 per cubic millimeter; and platelet count, at
least 100,000 per cubic millimeter), renal function
(serum creatinine, less than 1.5 times the upper limit of
normal), and liver function (bilirubin, not more than
1.5 times the upper limit of normal; aspartate amino-
transferase and alanine aminotransferase, not more
than 5 times the upper limit of normal); no coexisting
medical problem of sufficient severity to limit study
compliance.Dosage and drug administration
EGFR status of the tumor was determined by
immunoistochemical analysis of a paraffin-embedded
tumor specimen with the use of an EGFR diagnostic kit
(Dako Cytomation). Since 2006 attention has been
focused on intracellular mediators involved in the trans-
duction of EGFR signal to predict the efficacy of the treat-
ment and KRAS pathways have been investigated. (Lievre
et al. 2006; De Roock et al. 2007; Di Fiore et al. 2007a;
Khambata-Ford et al. 2007; Lievre et al. 2008). From
November 2008 we had the opportunity to analyse KRAS
oncogene status by the PCR/sequencing technique.
After screening, patients were enrolled to receive first
line chemotherapy with Folfiri (irinotecan 180 mg/m2 IV
over 90 minutes, day 1, concurrently with folinic acid
100 mg/m2 day 1–2 IV over 120 minutes followed by
fluorouracil 400 mg/m2 IV bolus, days 1,2, then fluoro-
uracil 1200 mg/m2/die intravenous infusion over 46
hours) plus bevacizumab 5 mg/Kg day1. Treatment was
administered every 2 weeks. If patients maintained at
least stable disease after 6 months of treatment they
continued therapy with bevacizumab 7.5 mg/Kg every 3
weeks as maintenance.
Patients showing disease progression underwent to
second line treatment with the same chemotherapy sche-
dule, but replacing monoclonal antibody with cetuximab
(first dose 400 mg/mq then 250 mg/mq weekly). If stable
disease was maintained after 6 months, patients continued
therapy with cetuximab alone with a dosage of 250 mg/mq
weekly until intolerable toxicity or progressive disease.
Disease progression was documented by computed
tomography (CT), magnetic resonance imaging (MRI) or
Positron Emission Tomography (PET).
Toxic effects were assessed according to the National
Cancer Institute Common Toxicity Criteria, version 3.
Modifications of the dose were made in cases of
hematologic or non-hematologic toxic effects.
The primary endpoint was the disease control rate
(DCR) defined as ORR plus stable disease ≥6 months.
The secondary endpoints included the overall response
rate (ORR), the progression-free survival (PFS), the
duration of response, the overall survival (OS) and the
toxicities.
All patients signed a consent form. The study was
approved by the institutional ethic committee.
Statistical analysis
The endpoint of this study is the disease control rate
(DRC defined as ORR plus stable disease ≥6 months).
This phase II trial is planned as a single-stage design
as described by A’Hern. A sample of 53 patients is con-
sidered sufficient to give an 80% probability of rejecting
a baseline disease control rate (DCR) of 35% with an
exact 5% one-sided significance test when the true DCR
Table 1 Baseline patient’s characteristics
Characteristics (N=54) N° of patients (%)
Median age (range) 65 (43–80)
Median follow-up from 1st line, months (range) 26 (8–65)
Median follow-up from 2nd line, months (range) 13 (3–51)
Sex Men 31 (57)
Women 23 (43)
ECOG performance status
0/1 36 (67)/18 (33)
Primary diagnosis
Colon cancer 42 (78)





Wild type (%) 31 (57)
Mutant Kras (%) 2 (4)
Unknown 21 (39)
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DCR (as previously defined) are observed.
All patients enrolled were considered the intention-to
-treat population (ITT). This population was evaluated
for the efficacy and safety analysis.
The standard summary statistics were used for both
continuous and discrete variables. The DCR and the
objective response rate were reported with its 95% confi-
dence interval.
The time to event analysis was performed according

























Figure 1 DCR survival curve for second line treatment (Kaplan Maiertest was used to assess differences between subgroups.
Significance was defined at the p<0.05 level.Results
Between January 2008 to January 2010, 54 patients with
positive EGFR status after progression of the disease at
first line with Folfiri plus bevacizumab were enrolled to
receive second line combination treatment with Folfiri
plus cetuximab (FC) followed by cetuximab (C) alone if
stable disease was maintained. The analysis of Kras
status was feasible and performed for 33 (61%) tumor
specimens. Patient’s characteristics are shown in Table 1.
Median cycles of first line treatment were 12 (range 4–
16) for 35 patients and 8 (1–23) cycles of bevacizumab
alone for 32 patients with at least stable disease.
Median cycles of second line chemotherapy with
Folfiri plus cetuximab were 9 (range 1–14) for 19 pa-
tients and 7 (range 2–15) for 12 patients that continued
treatment with cetuximab alone for maintenance.
The Disease Control Rate was achieved in 64.8 percent
(CI 95% 52.1-77.5) of the patients who received second
line treatment with Folfiri plus cetuximab (Figure 1 and
Table 2).
The overall response rate (the rate of complete
response plus the rate of partial response, ORR) was 22.2
percent (95% confidence interval, 11.1 to 33.3 percent)
(Table 3).
At first line chemotherapy 44.5% of the patients had a
complete or partial response; 33.3% of them continued
to be responsive to second line with the same chemo-
therapy regimen plus cetuximab. Of special interest is
the finding that 13.3% of patients with stable or progres-







Table 2 Kaplan Maier estimate for overall response rate













No 78.6 49.7 11.8 12(9–15)
Yes 100 91.7 55.0 27(11–43)
DCR
No 52.3 5.3 - 7(5–9) <0.0001
Yes 100 88.2 33.8 20(15–24)
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response was 6 months (CI 95% 4–8). The clinical bene-
fit was 7 months (range 1–21).
The median progression-free survival was 7 months
(CI 95% 6–8). The percentage of patients free of
progression at year one was 15.9%. The median overall
survival for second line treatment was 14 months (CI 95%
11–17). At year one 58.9 percent of patients were alive
and 21.8 percent at years two (Figure 2 and Table 2).
The median OS of all patients from first line chemo-
therapy with Folfiri plus bevacizumab was twenty-seven
months (CI 95% 25–29). The overall survival for 32
(59.3%) patients that had DCR at first and second line
treatment was 33 months (CI95% 26.4-39.6).
In Table 4 and 5 toxicities were shown. The majority
of patients presented grade 1–2 side effects.
Data showed that no increasing of toxicities was noted
moving from first line to second line treatment although
patients restarted the same chemotherapy regimen.
First line chemotherapy with Folfiri plus bevacizumab
was well tolerated. Only 3 patients had grade 4 neutro-
penia. No other grade 4 toxicities were presented. No
bleeding, thromboembolism or severe hypertension were
shown. Dose reduction of irinotecan was made for only
three patients for side effects reasons.
In the group of patients treated with cetuximab acne-
like rash occurred in 70% of patients (39% grade ≥2; noTable 3 Overall response rate
First line Second line
N. (%) N. (%)
Best Overall Response 22 (44.5) 12 (22.2)*
Complete Response 5 (9.3) 0 (0)
Partial Response 19 (35.2) 12 (22.2)
Stable Disease 22(40.7) 23 (46.2)
Progressive Disease 8 (14.8) 19 (35.2)
Disease Control Rate 44 (81.5) 35 (64.8)**
* CI 95% 11.1-33.3
**CI 95% 52.1-77.5grade 4 toxicity was observed). No severe gastrointes-
tinal side effects were shown.
57 percent of patients reached and made it to third
line chemotherapy. Due to acceptable performance
status 15 patients were administered to FOLFOX4 chemo-
therapy regimen (standard dose or adjusted dose if neces-
sary). For eight patients only monotherapy regimen with
fluoropyrimidines was possible.
To date nine patients are alive and two of them are
still in treatment with chemotherapy.
Discussion
The analysis of literature shows that metastatic colorectal
cancer patients, who have received chemotherapy may
survive for about twenty-four months. If the effective drugs
have failed, there are no other options (Cunningham et al.
2004a; Hurwitz et al. 2004).
This study analysed a feasible sequence of monoclonal
antibodies maintaining the same chemotherapy regimen.
The results confirmed the feasibility and efficacy of
treatment.
In accordance with the outcome of phase III trials the
response rate in first line treatment reached about 44%
and second line showed about 22% (Cunningham et al.
2004a; Hurwitz et al. 2004).
The changing of bevacizumab after progression of
disease with cetuximab produced an interesting survival
rate in this sample of patients without resulting in an
increase of toxicities.
Indeed, the median overall survival from first line
treatment was 27 months, that reached 33 months for
patients that maintained DCR at first and second line
therapy.
From first line treatment 8 (14.8%) patients had
progressive disease at six months of chemotherapy and
started second line chemotherapy. Among them, 6
patients had progressive disease at Folfiri plus cetuximab
and the resulting overall survival was 14 months for
these patients. The other two patients had clinical bene-
fit (DCR) at second line treatment of 14 and 15 months
respectively and the overall survival was 21 and 23
months respectively. The clinical benefit was 7 months
(range 1–21).
The achievement of a new responsiveness in these
progressive patients had an impact on survival. This
result was allowed by the changing monoclonal antibody.
Despite the use of the same chemotherapy for about
twelve consecutive months, the regimen was well tolerated
and there was no evidence of increase of the frequency or
severity of the characteristic toxicities associated with
treatment.
Moreover, it is very important to emphasize that the
population included also older patients with 21.5% of






























Figure 2 Responder survival curve for second line therapy (Kaplan Maier Method).
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rates.
In this study the number of patients receiving third
line chemotherapy is encouraging (57 percent) and it
underlines the feasibility of this sequence, which helps
an acceptable quality of life for patients.
These data suggest that this sequential combination
therapy is active, however, due to the small number of
patients this study is limited and the KRAS mutation
status was not available for all patients.
Furthermore, it should also be noted that at the begin-
ning of the study a high percentage of patients (76%)
had only a single distant metastatic site.
When the study started no data were available for the
efficacy of cetuximab plus chemotherapy in the first line
treatment of metastatic colorecatal cancer.Table 4 Main adverse events at first line chemotherapy
Grading
0 1 2 3 4
Neutropenia 25 11 6 9 3
Anaemia 41 13 0 0 0
Skin toxicity 0 1 0 0 0
Fatigue 29 10 13 2 0
Nausea/Vomiting 40 13 1 0 0
Hypertension 43 10 1 0 0
Bleeding 41 13 0 0 0
Proteinuria 49 3 2 0 0
Diarrhea 29 12 11 2 0
Stomatitis 37 6 11 0 0Recently, first line treatment with cetuximab has been
approved in combination with chemotherapy and the
benefits of cetuximab was limited to patients with KRAS
wild-type tumors, reducing the risk of progression of
metastatic colorectal cancer.
In this study for only 33 patients the analysis of KRAS
status was performed; an adequate selection of patients
could improve survival.
In conclusion, this research underlines the need for
more information about a better sequence of chemother-
apy regimens for this kind of patients.
It would be interesting to evaluate in a larger rando-
mized trial what is the better sequence of drugs that can
allow patients to obtain better responses and consequently
a longer survival along with an acceptable quality of life.Table 5 Main adverse events at second line
chemotherapy
Grading
0 1 2 3 4
Neutropenia 39 7 6 2 0
Anaemia 40 12 1 1 0
Skin toxicity 16 17 17 4 0
Fatigue 37 8 8 1 0
Nausea/vomiting 46 8 0 0 0
Hypertension 54 0 0 0 0
Bleeding 54 0 0 0 0
Proteinuria 54 0 0 0 0
Diarrhea 28 14 11 1 0
Stomatitis 34 10 12 0 0
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